Charlie Young: This is Charlie Young on for Geoff. So I guess I have kind of two part questions. First is, I’m wondering whether you can provide details in terms of why the biomarkers have been tested in this trial for REVEAL 2. And maybe one appetite is, is the reason why we’re not seeing a statistic here due to the fact that the number of patients enrolled were relatively small. So is the trial on the power? And that’s the reason why we’re going to see a statistic in the biomarkers to like the patients? And I have a follow-up after this.
Jacqueline Shea : I think those are interesting questions. So as you may recollect from the call, the biomarker-selected population was selected using our investigational biomarker. I’m going to hand it over to Mike now to provide some further details as to how we selected that biomarker and what the potential implications might be going forward. Mike?
Michael Sumner: Yes. So at present, we have not disclosed what our biomarker signal was. And we’ll do that, I think, in context of a full analysis of both what we saw on REVEAL 1 as well as what we saw in REVEAL 2, as without the sort of full detailed sort of population and the other impacts that can affect treatment efficacy. I think it would just be a little premature for us to talk about that at the moment. I mean to your comment around power, I mean, obviously, we did expect a higher number of subjects to have the biomarker based on what we saw in REVEAL 1. But really, it wasn’t a powering issue with the study. I mean we genuinely saw a lower efficacy rate from the biomarker selective population. So that’s what really makes us want to dig into the data and understand what went on in that biomarker population so that we can come back and tell people what really happened, and we’re just not at the stage to do that at the moment, but we will be doing that work.
Jacqueline Shea : Yes. And if I can just add to that, Mike. I mean, we should remember that these were trials that were not enrolled on the basis of the biomarker. The biomarker was applied retrospectively. And we have developed or defined the biomarker signature based on what we had seen in REVEAL 1. And I think this was part of the reason why in discussions with the FDA, it became clear that REVEAL 2 would need to be exploratory for that biomarker selective population.
Charlie Young : And maybe just a follow-up on a different question. Can you — so you mentioned in the press release that the cash run rate into first quarter of 2025. Can you just provide some details on the assumptions in terms of your program? And how would the — I guess, the next steps in terms of development for RRP and maybe the GBM will impact that cash runway? Thank you.
Peter Kies : I’ll take that.
Jacqueline Shea : Thanks, Peter.
Peter Kies : So what you’re seeing is the wind down — there’ll be a few wind down costs from our COVID program, but you’re seeing the expenses shifting over into the RRP programs. and the slight increase in the GBM programs. We still have money going into our annual programs. and then an increase in 5PSP and 3PSP developments to get those to commercial ready. Right now, probably one of the lead programs is the RP and that does anticipate that we get the Phase 3 trial started upon regulatory approval from the FDA to be able to move forward toward the end of the year, third quarter, beginning of fourth quarter. And we will cover the majority of those Phase 3 costs.
Operator: The next question is from Roger Song with Jefferies. Please go ahead.
